Emerald Health
Therapeutics, Inc. (TSXV:EMH) (OTCQX:EMHTF) ("Emerald" or the “Company”)
closed today its prospectus sale (the “Offering”) to a single Canadian
institutional accredited investor (the “Investor”) announced on January
3, 2018. Pursuant to the Offering, the Company has issued 3,000,000
units (the “Units”) at a price per Unit of $5.00, for gross proceeds of
$15,000,000.
Each Unit consisted of
one common share of the Company and one common share purchase warrant
(a “Warrant”). Each Warrant will entitle the Investor to acquire one
common share of the Company (a “Warrant Share”) at a price of $6.00 per
Warrant Share for a period of 36 months following the closing of the
Offering. In the event that the closing sale price of the Company’s
common shares (the “Common Shares”) on the TSX Venture Exchange is
greater than $8.00 per Common Share for a period of 10 consecutive
trading days at any time after the closing of the Offering, the Company
may accelerate the expiry date of the Warrants by giving notice to the
Investor and in such case the Warrants will expire on the 30th day after
the date on which such notice is given by the Company.
The
Company intends to use the net proceeds of the Offering for its
production and R&D-related growth plans, working capital and general
corporate purposes.
The Units were offered by
way of a shelf prospectus supplement filed in all of the provinces of
Canada, except Quebec, pursuant to National Instrument 44-101 - Short Form Prospectus Distributions.
The
previously announced purchase by the Investor of 2,000,000 Common
Shares (the “Secondary Sale”) from Emerald Health Sciences Inc., a
control person of the Company, at a price of $5.00 per share, is
expected to close separately.
About Emerald Health Therapeutics Inc.
Emerald Health Therapeutics, Inc. (TSXV:EMH) (OTCQX:EMHTF) operates through Emerald Health Botanicals Inc. ("Botanicals"), a wholly owned subsidiary and Licensed Producer under Canada’s Access to Cannabis for Medical Purposes Regulations. Through Botanicals, Emerald is authorized to produce and sell dried medical cannabis flower and medical cannabis oil. It currently operates an indoor facility in Victoria, BC, and is building a 500,000 s.f. greenhouse on 32 acres in Metro Vancouver, with expansion potential to 1 million s.f. to serve the anticipated legal Canadian adult-use cannabis market starting in 2018. Emerald also owns 50% of Pure Sunfarms Inc., a partnership with Village Farms International Inc. that is converting an existing 1.1 million s.f. greenhouse in Delta, BC from growing tomatoes to growing cannabis. Emerald’s team is highly experienced in life sciences, product development and large-scale agribusiness. Emerald is part of the Emerald Health group, which is broadly focused on developing pharmaceutical, botanical and nutraceutical products designed to provide wellness and medical benefits by interacting with the human body’s endocannabinoid system.
Emerald Health Therapeutics, Inc. (TSXV:EMH) (OTCQX:EMHTF) operates through Emerald Health Botanicals Inc. ("Botanicals"), a wholly owned subsidiary and Licensed Producer under Canada’s Access to Cannabis for Medical Purposes Regulations. Through Botanicals, Emerald is authorized to produce and sell dried medical cannabis flower and medical cannabis oil. It currently operates an indoor facility in Victoria, BC, and is building a 500,000 s.f. greenhouse on 32 acres in Metro Vancouver, with expansion potential to 1 million s.f. to serve the anticipated legal Canadian adult-use cannabis market starting in 2018. Emerald also owns 50% of Pure Sunfarms Inc., a partnership with Village Farms International Inc. that is converting an existing 1.1 million s.f. greenhouse in Delta, BC from growing tomatoes to growing cannabis. Emerald’s team is highly experienced in life sciences, product development and large-scale agribusiness. Emerald is part of the Emerald Health group, which is broadly focused on developing pharmaceutical, botanical and nutraceutical products designed to provide wellness and medical benefits by interacting with the human body’s endocannabinoid system.
Please visit www.emeraldhealth.ca for more information or contact:
No comments:
Post a Comment